Skip to main content

Table 1 Characteristics of patients

From: The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients

Number of patients 98
Age (median, range) 58 (19–89)
Sex
 M 57
 F 41
Onset
 Primary 78 (80%)
 Post-MDS/MPN 10 (10%)
 Post-therapy 10 (10%)
Blasts % (median, range) 70 (20-95)
WBC, (median, range) x 109/L 7.9 (0.8–35)
Hb, (median, range) x g/dL 9.6 (4–15.5)
PLT, (median, range) x 109/L 50.5 (1.7–656)
Karyotype
 Normal 40 (41%)
 Abnormal 43 (44%)
 Complex 15 (15%)
WHO classification
 With recurrent abnormalities 44 (44%)
 MDS-related 10 (10%)
 Post-therapy 10 (10%)
 Provisional entities 12 (12%)
 NOS 19 (19%)
 Myeloid sarcoma 3 (3%)
ELN risk
 Favorable 25 (25.5%)
 Intermediate 55 (56.1%)
 Adverse 18 (18.4%)
Treatment
 3 + 7 55 (56.1%)
 Demethylating agents 13 (13.3%)
 LAM 1310 17 (17.3%)
 Supportive therapies 13 (13.3%)
 AlloBMT 22 (22%)